Bens G et al. |
Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption. |
2003 |
Br. J. Dermatol. |
pmid:12890237
|
Reich K et al. |
Topical tacrolimus for pyoderma gangrenosum. |
1998 |
Br. J. Dermatol. |
pmid:9892935
|
Kyllönen H et al. |
Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. |
2004 |
Br. J. Dermatol. |
pmid:15214906
|
Danby SG and Cork MJ |
The effects of pimecrolimus on the innate immune response in atopic dermatitis. |
2013 |
Br. J. Dermatol. |
pmid:23362967
|
Schmitt J et al. |
Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. |
2011 |
Br. J. Dermatol. |
pmid:20819086
|
Schauber J et al. |
Topical treatment of perianal eczema with tacrolimus 0.1%. |
2009 |
Br. J. Dermatol. |
pmid:19575757
|
Rustin MH |
The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. |
2007 |
Br. J. Dermatol. |
pmid:17854353
|
Bunker CB |
Male genital lichen sclerosus and tacrolimus. |
2007 |
Br. J. Dermatol. |
pmid:17854373
|
Remitz A et al. |
Tacrolimus ointment improves psoriasis in a microplaque assay. |
1999 |
Br. J. Dermatol. |
pmid:10417522
|
Braza TJ et al. |
Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. |
2003 |
Br. J. Dermatol. |
pmid:12828755
|
Vidal D and Alomar A |
Successful treatment of periostomal pyoderma gangrenosum using topical tacrolimus. |
2004 |
Br. J. Dermatol. |
pmid:14996128
|
Lan CC et al. |
FK506 (tacrolimus) and endothelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin. |
2011 |
Br. J. Dermatol. |
pmid:21039414
|
Kanekura T et al. |
Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. |
2003 |
Br. J. Dermatol. |
pmid:12588393
|
Vente C et al. |
Erosive mucosal lichen planus: response to topical treatment with tacrolimus. |
1999 |
Br. J. Dermatol. |
pmid:10233234
|
Lyon CC et al. |
Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. |
1999 |
Br. J. Dermatol. |
pmid:10233300
|
Jolles S et al. |
Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. |
1999 |
Br. J. Dermatol. |
pmid:10233301
|
Walker SL et al. |
The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. |
2002 |
Br. J. Dermatol. |
pmid:12174136
|
Anstey A |
Therapeutic advances and shift in disease paradigm for atopic dermatitis. |
2008 |
Br. J. Dermatol. |
pmid:19036027
|
Katoh N et al. |
Cutaneous sarcoidosis successfully treated with topical tacrolimus. |
2002 |
Br. J. Dermatol. |
pmid:12100200
|
McElwee KJ et al. |
Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. |
1997 |
Br. J. Dermatol. |
pmid:9390322
|
Harper J et al. |
First experience of topical SDZ ASM 981 in children with atopic dermatitis. |
2001 |
Br. J. Dermatol. |
pmid:11298537
|
Luger T et al. |
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. |
2001 |
Br. J. Dermatol. |
pmid:11298538
|
Lan CC et al. |
FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. |
2004 |
Br. J. Dermatol. |
pmid:15377358
|
Piram M et al. |
Short- and long-term outcome of linear morphoea in children. |
2013 |
Br. J. Dermatol. |
pmid:24032480
|
Reitamo S et al. |
0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. |
2004 |
Br. J. Dermatol. |
pmid:15030341
|
Chuh AA |
The application of topical tacrolimus in vesicular pemphigoid. |
2004 |
Br. J. Dermatol. |
pmid:15030368
|
Gollnick H et al. |
Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. |
2008 |
Br. J. Dermatol. |
pmid:18341665
|
Erdogan M et al. |
Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. |
2002 |
Br. J. Dermatol. |
pmid:12072063
|
Hjelmgren J et al. |
Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. |
2007 |
Br. J. Dermatol. |
pmid:17263826
|
Volz T et al. |
Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. |
2008 |
Br. J. Dermatol. |
pmid:18647310
|
Rigopoulos D et al. |
Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. |
2009 |
Br. J. Dermatol. |
pmid:19120329
|
Oranje AP et al. |
Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. |
2009 |
Br. J. Dermatol. |
pmid:18795918
|
Wataya-Kaneda M et al. |
A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. |
2011 |
Br. J. Dermatol. |
pmid:21692771
|
Spergel JM et al. |
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. |
2007 |
Br. J. Dermatol. |
pmid:17573885
|
Niwa Y et al. |
Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. |
2003 |
Br. J. Dermatol. |
pmid:14632799
|
Ko MJ and Chu CY |
Topical tacrolimus therapy for localized bullous pemphigoid. |
2003 |
Br. J. Dermatol. |
pmid:14632824
|
Böhm M et al. |
Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. |
2004 |
Br. J. Dermatol. |
pmid:15327576
|
Langeland T and Engh V |
Topical use of tacrolimus and squamous cell carcinoma on the penis. |
2005 |
Br. J. Dermatol. |
pmid:15656830
|
Kreuter A et al. |
Pimecrolimus 1% cream for perianal atopic dermatitis. |
2005 |
Br. J. Dermatol. |
pmid:15656832
|
Fiorentino DF et al. |
The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. |
2011 |
Br. J. Dermatol. |
pmid:21166661
|
Brouard MC et al. |
Erosive pustular dermatosis of the leg: report of three cases. |
2002 |
Br. J. Dermatol. |
pmid:12366427
|
Lewis FM and Neill SM |
Safety of calcineurin inhibitors in the management of lichen sclerosis. |
2007 |
Br. J. Dermatol. |
pmid:17535239
|
Connolly M and Kennedy C |
Exfoliative cheilitis successfully treated with topical tacrolimus. |
2004 |
Br. J. Dermatol. |
pmid:15270904
|
Healy E et al. |
Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. |
2011 |
Br. J. Dermatol. |
pmid:21083544
|
Hengge UR et al. |
Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. |
2006 |
Br. J. Dermatol. |
pmid:17034535
|
Kang HY and Choi YM |
FK506 increases pigmentation and migration of human melanocytes. |
2006 |
Br. J. Dermatol. |
pmid:17034537
|
Lübbe J and Sorg O |
Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. |
2004 |
Br. J. Dermatol. |
pmid:15606530
|
Tzung TY et al. |
Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. |
2007 |
Br. J. Dermatol. |
pmid:17199600
|
Lonowski S et al. |
Vitiligo: a potential autoimmune sequela of DRESS syndrome. |
2016 |
Br. J. Dermatol. |
pmid:27038429
|
Gottlieb AB et al. |
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. |
2005 |
Br. J. Dermatol. |
pmid:15948985
|
Bhol KC and Schechter PJ |
Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. |
2005 |
Br. J. Dermatol. |
pmid:15948987
|
Reitamo S et al. |
A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. |
2005 |
Br. J. Dermatol. |
pmid:15948994
|
Bos JD |
Topical tacrolimus and pimecrolimus are not associated with skin atrophy. |
2002 |
Br. J. Dermatol. |
pmid:11903264
|
Wolff K et al. |
Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. |
2005 |
Br. J. Dermatol. |
pmid:15948996
|
Rigopoulos D et al. |
Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. |
2005 |
Br. J. Dermatol. |
pmid:15949015
|
Kirtschig G et al. |
Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. |
2002 |
Br. J. Dermatol. |
pmid:12207624
|
Feldmann KA et al. |
Is topical tacrolimus effective in alopecia areata universalis? |
2002 |
Br. J. Dermatol. |
pmid:12410729
|
Sigurgeirsson B and Luger T |
A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response. |
2017 |
Br. J. Dermatol. |
pmid:28940181
|
Pereira U et al. |
Mechanisms of the sensory effects of tacrolimus on the skin. |
2010 |
Br. J. Dermatol. |
pmid:20302583
|
Ho N et al. |
A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. |
2011 |
Br. J. Dermatol. |
pmid:21457214
|
Rigopoulos D et al. |
Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. |
2006 |
Br. J. Dermatol. |
pmid:16792767
|
Weissenbacher S et al. |
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. |
2007 |
Br. J. Dermatol. |
pmid:17493072
|
Williams HC |
Preventing eczema flares with topical corticosteroids or tacrolimus: which is best? |
2011 |
Br. J. Dermatol. |
pmid:21271989
|
Chohan R et al. |
Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. |
2003 |
Br. J. Haematol. |
pmid:14510951
|
Mehta RS et al. |
Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. |
2016 |
Br. J. Haematol. |
pmid:26947769
|
Pulsipher MA et al. |
A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). |
2009 |
Br. J. Haematol. |
pmid:19744131
|
Murata M et al. |
A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. |
1999 |
Br. J. Haematol. |
pmid:10354150
|
Armand P et al. |
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. |
2016 |
Br. J. Haematol. |
pmid:26729448
|
Wong R et al. |
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. |
2003 |
Br. J. Haematol. |
pmid:12823354
|
Feliu J et al. |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. |
2014 |
Br. J. Haematol. |
pmid:24962133
|
Couriel DR et al. |
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. |
2005 |
Br. J. Haematol. |
pmid:16042691
|
Mollee P et al. |
Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. |
2001 |
Br. J. Haematol. |
pmid:11328304
|
Kida A et al. |
Calcineurin-inhibitor pain syndrome following haematopoietic stem cell transplantation. |
2004 |
Br. J. Haematol. |
pmid:15257699
|
Boulad F et al. |
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. |
2000 |
Br. J. Haematol. |
pmid:11167755
|
Dusting GJ et al. |
Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. |
1999 |
Br. J. Pharmacol. |
pmid:10510443
|
Quintá HR and Galigniana MD |
The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. |
2012 |
Br. J. Pharmacol. |
pmid:22091865
|
Gil V et al. |
Effects of inhibitors of hydrogen sulphide synthesis on rat colonic motility. |
2011 |
Br. J. Pharmacol. |
pmid:21486289
|
Klettner A and Herdegen T |
The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response. |
2003 |
Br. J. Pharmacol. |
pmid:12642403
|
Magari K et al. |
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. |
2003 |
Br. J. Pharmacol. |
pmid:12839866
|
Simon N et al. |
Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria. |
2003 |
Br. J. Pharmacol. |
pmid:12540528
|
Øzbay LA et al. |
Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. |
2011 |
Br. J. Pharmacol. |
pmid:20825407
|
Bader A et al. |
Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. |
2000 |
Br. J. Pharmacol. |
pmid:10694240
|
Squadrito F et al. |
Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. |
1999 |
Br. J. Pharmacol. |
pmid:10385251
|
Price RD et al. |
FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway. |
2003 |
Br. J. Pharmacol. |
pmid:14559856
|
Hortelano S et al. |
Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. |
1999 |
Br. J. Pharmacol. |
pmid:10205001
|
Harrison S et al. |
Stimulation of airway sensory nerves by cyclosporin A and FK506 in guinea-pig isolated bronchus. |
1998 |
Br. J. Pharmacol. |
pmid:9884067
|
Eum SY et al. |
Inhibition by the immunosuppressive agent FK-506 of antigen-induced airways eosinophilia and bronchial hyperreactivity in mice. |
1997 |
Br. J. Pharmacol. |
pmid:9117088
|
Deters M et al. |
Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. |
2002 |
Br. J. Pharmacol. |
pmid:12055139
|
MacMillan D and McCarron JG |
Regulation by FK506 and rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR. |
2009 |
Br. J. Pharmacol. |
pmid:19785652
|
Waschulewski IH et al. |
Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. |
1993 |
Br. J. Pharmacol. |
pmid:7683567
|
Weidelt T and Isenberg G |
Augmentation of SR Ca(2+) release by rapamycin and FK506 causes K(+)-channel activation and membrane hyperpolarization in bladder smooth muscle. |
2000 |
Br. J. Pharmacol. |
pmid:10742283
|
Bas E et al. |
Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. |
2012 |
Br. J. Pharmacol. |
pmid:22320124
|
Gardiner SM et al. |
Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. |
2004 |
Br. J. Pharmacol. |
pmid:14744807
|
Pahl A et al. |
Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy. |
2002 |
Br. J. Pharmacol. |
pmid:11959794
|
Sakuma S et al. |
FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. |
2000 |
Br. J. Pharmacol. |
pmid:10928971
|
Harrison CA et al. |
Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. |
2007 |
Br. J. Pharmacol. |
pmid:17200674
|
Zuany-Amorim C et al. |
Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. |
1993 |
Br. J. Pharmacol. |
pmid:7694762
|
Lampen A et al. |
Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. |
1996 |
Br. J. Pharmacol. |
pmid:8732283
|
Li J et al. |
Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. |
2005 |
Br. J. Pharmacol. |
pmid:15821752
|
Oetjen E et al. |
The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-induced CREB transcriptional activity at the coactivator level. |
2005 |
Br. J. Pharmacol. |
pmid:15711594
|